BIOMAT Database Logo BIOMAT Database Logo

Discovering transthyretin amyloid fibril inhibitors by limited screening. 1998

P W Baures, and S A Peterson, and J W Kelly
Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.

Insoluble protein fibrils, resulting from the self-assembly of a conformational intermediate are implicated to be the causative agent in several human amyloid diseases including familial amyloid polyneuropathy (FAP) and senile systemic amyloidosis (SSA). These diseases are associated with transthyretin (TTR) amyloid fibrils, which appear to form in the acidic partial denaturing environment of a lysosome or endosome. Here we identify several structural classes of small molecules that are capable of inhibiting the TTR conformational changes facilitating amyloid fibril formation. A small molecule inhibitor that stabilizes the normal conformation of a protein is desirable as a promising approach to treat amyloid diseases and to rigorously test the amyloid hypothesis, the apparent causative role of amyloid fibrils in amyloid disease.

UI MeSH Term Description Entries
D011228 Prealbumin A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease. Proalbumin,Transthyretin
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D005439 Flufenamic Acid An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) Dignodolin,Acid, Flufenamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000682 Amyloid A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease. Amyloid Fibril,Amyloid Fibrils,Amyloid Substance,Fibril, Amyloid,Fibrils, Amyloid,Substance, Amyloid
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D000880 Anthraquinones Compounds based on ANTHRACENES which contain two KETONES in any position. Substitutions can be in any position except on the ketone groups. Anthracenedione,Anthracenediones,Anthranoid,Anthraquinone,Anthraquinone Compound,Anthraquinone Derivative,Dianthraquinones,Dianthrones,Anthranoids,Anthraquinone Compounds,Anthraquinone Derivatives,Compound, Anthraquinone,Derivative, Anthraquinone
D001577 Benzophenones Derivatives of benzophenone (with the structural formula phenyl-(C
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

P W Baures, and S A Peterson, and J W Kelly
Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry.
June 2002, Structure (London, England : 1993),
P W Baures, and S A Peterson, and J W Kelly
Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
March 2005, Journal of medicinal chemistry,
P W Baures, and S A Peterson, and J W Kelly
Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors.
July 2013, Organic & biomolecular chemistry,
P W Baures, and S A Peterson, and J W Kelly
Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.
January 1999, Bioorganic & medicinal chemistry letters,
P W Baures, and S A Peterson, and J W Kelly
Screening for pharmacologic inhibitors of amyloid fibril formation.
January 1999, Methods in enzymology,
P W Baures, and S A Peterson, and J W Kelly
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action.
June 2003, Angewandte Chemie (International ed. in English),
P W Baures, and S A Peterson, and J W Kelly
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.
May 2001, Proceedings of the National Academy of Sciences of the United States of America,
P W Baures, and S A Peterson, and J W Kelly
Oxidation inhibits amyloid fibril formation of transthyretin.
December 2006, The FEBS journal,
P W Baures, and S A Peterson, and J W Kelly
Identification of Transthyretin Fibril Formation Inhibitors Using Structure-Based Virtual Screening.
August 2017, ChemMedChem,
P W Baures, and S A Peterson, and J W Kelly
Inhibition of amyloid beta fibril formation by monomeric human transthyretin.
July 2018, Protein science : a publication of the Protein Society,
Copied contents to your clipboard!